Hi-Clearance Inc. AI Stock Analysis
Hi-Clearance Inc. (1788) AI Stock Analysis
Hi-Clearance Inc.
(TPEx:1788)
The overall score is constrained by weak technical momentum and deteriorating cash flows, which are significant near-term risks. The company's strong balance sheet and attractive valuation, including a high dividend yield, provide a solid fundamental floor, but the bearish technical picture and declining free cash flow are the most impactful factors currently weighing on the stock.
Hi-Clearance Inc. (1788) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 5.57B
- Dividend Yield
- 5.58%
- Average Volume (3M)
- 19.73K
- Price to Earnings (P/E)
- 14.1
- Beta (1Y)
- 0.02
- Revenue Growth
- 7.58%
- EPS Growth
- 13.04%
- Country
- TW
- Employees
- 150
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Medical - Specialties
Hi-Clearance Inc. Business Overview & Revenue Model
Company Description
Established in 1989 and headquartered in New Taipei City, Taiwan, Hi-Clearance Inc. is a prominent supplier of medical devices and associated services throughout Taiwan. The company's comprehensive product range addresses various healthcare sectors,...
Hi-Clearance Inc. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong with low debt and steady ROE, and revenue growth has resumed. However, declining EBIT margins and a sharp two-year slide in free cash flow weigh on the overall score, indicating operational cash conversion challenges.
Income Statement
62PositiveBalance Sheet
75PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.41B | 4.28B | 4.07B | 3.90B | 4.69B | 3.68B |
| Gross Profit | 1.22B | 1.14B | 1.07B | 1.02B | 1.05B | 968.97M |
| EBITDA | 631.99M | 620.80M | 636.07M | 580.00M | 625.93M | 595.93M |
| Net Income | 391.96M | 368.51M | 359.69M | 347.98M | 366.43M | 348.59M |
Balance Sheet | ||||||
| Total Assets | 5.29B | 5.08B | 4.96B | 4.62B | 4.51B | 4.44B |
| Cash, Cash Equivalents and Short-Term Investments | 564.80M | 599.45M | 545.53M | 453.10M | 417.23M | 404.56M |
| Total Debt | 1.16B | 1.06B | 971.65M | 644.74M | 1.03B | 1.14B |
| Total Liabilities | 2.34B | 2.03B | 1.96B | 1.63B | 2.07B | 2.13B |
| Stockholders Equity | 2.95B | 3.05B | 3.00B | 2.98B | 2.44B | 2.30B |
Cash Flow | ||||||
| Free Cash Flow | 263.60M | 295.39M | 225.55M | 371.54M | 300.49M | 137.28M |
| Operating Cash Flow | 354.70M | 400.70M | 510.12M | 433.49M | 403.16M | 287.79M |
| Investing Cash Flow | -119.56M | -98.43M | -377.19M | -66.45M | -82.61M | -158.04M |
| Financing Cash Flow | -279.22M | -241.32M | -122.33M | -288.44M | -342.13M | -196.90M |
Hi-Clearance Inc. Peers Comparison
Overall Rating
TW:412669Neutral
TW:416665Neutral
TW:173464Neutral
TW:416359Neutral
TW:178858Neutral
TW:179945Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | TWD 5.34B | 12.53 | ― | 6.11% | 1.32% | 7.25% | |
| 65Neutral | TWD 4.93B | 18.58 | ― | ― | ― | ― | |
| 64Neutral | TWD 5.87B | 16.72 | ― | 3.24% | 2.44% | -3.96% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 59Neutral | TWD 6.31B | 20.33 | ― | 2.81% | 4.16% | 40.82% | |
| 58Neutral | TWD 5.59B | 14.13 | ― | 5.58% | 7.58% | 13.04% | |
| 45Neutral | TWD 6.22B | -266.81 | ― | ― | 59.53% | 83.16% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1788 | Hi-Clearance Inc. | 125.50 | -4.45 | -3.42% | |
| TW:1734 | Sinphar Pharmaceutical Co. Ltd. | 29.10 | 1.26 | 4.51% | |
| TW:1799 | Easywell Biomedicals, Inc. | 25.00 | -8.55 | -25.48% | |
| TW:4126 | Pacific Hospital Supply Co., Ltd. | 73.60 | -9.81 | -11.76% | |
| TW:4163 | Intai Technology Corp. | 124.50 | 28.42 | 29.58% | |
| TW:4166 | Orient Pharma Co., Ltd. | 20.30 | -3.60 | -15.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
